Expression of CD95(Fas) by gene transfer does not sensitize K562 to Fas-killing

Hematology and Cell Therapy

Volumn 39, Issue 2, 1997, Pages 75-78

  Munker, R ^a,b   Marini, F ^a   Jiang, S ^a   Savary, C ^a   Owen Schaub, L ^a   Andreeff, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CD95 Fas; gene transfer; K562

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; ARTICLE; CELL STRAIN K 562; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; MYELOID LEUKEMIA;

EID: 0030843606     PISSN: 14302772     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-997-0075-7     Document Type: Article

References (20)

1. Alderson MR, Tough TW, Davis-Smith T, et al (1995) Fas ligand mediates activation-induced death in human T lymphocytes. J Exp Med 181:71-77
2. Dhein J, Walczak H, Baumler C, et al (1995) Autocrine T-cell suicide mediated by Apo-1 (Fas/CD95). Nature 373:438-441
3. Guo BC, Saxon A (1995) B cell lines from a subset of patients with common variable immunodeficien-cy undergo enhanced apoptosis with an increased display of CD95(Apo-1/Fas), diminished CD38 expression and decreased IgG and IgA production. Cell Immunol 166:83-92
4. Hanania EG, Kavanagh J, Hortobagyi G, et al (1995) Recent advances in the application of gene therapy to human disease. Am J Med 99: 537-552
5. Lotzova E, Savary CA, Champlin RE (1975) Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. J Immunol 150: 5263-5269
6. Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 45: 321
7. + human marrow cells is induced by interferon and tumor necrosis factor and potentiates cytokine- mediated hematopoietic suppression in vitro. Blood 85: 3183
8. Montel AH, Bochan MR, Goebel WS, et al (1995) Fas-mediated cytotoxicity remains intact in perform and granzyme B antisense transfectants of a human NK-like cell line. Cell Immunol 165: 312-317
9. Munker R, Andreeff M (1996) Induction of death-(CD95/FAS), activation- and adhesion- (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-α and IFN-γ. Cytokines Mol Ther 2: 147-150
10. Munker R, Lübbert M, Yonehara S, et al (1995) Expression of the Fas antigen on primary human leukemia cells. Ann Hematol 70: 15-17
11. Nickoloff JA (1995) Animal cell electroporation and electrofusion. In: Walker JM (ed) Methods in molecular biology, vol. 48. Humana, Totowa
12. Owen-Schaub LB, Radinsky R, Kruzel E, et al (1994) Anti-Fas on non-hematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res 54: 1580-1586
13. Owen-Schaub LB, Zhang W, Cusack JC, et al (1995) Wild-type p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15: 3032-3040
14. Rieux-Laucat F, Le Deist F, Hivroz C, et al (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349
15. Robertson MJ, Manley TJ, Pichert G, et al (1995) Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymph 17: 51-61
16. Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76: 959-962
17. Trauth BC, Klas C, Peters AMJ, et al (1989) Monoclonal anti-body-mediated tumor regression by induction of apoptosis. Science 245: 301-305
18. Vile R, Russell SJ (1994) Gene transfer technologies for the gene therapy of cancer. Gene Ther 1: 88-98
19. Weller M, Malipiero U, Rensing-Ehl A, et al (1995) Fas/Apo-1 gene transfer for human malignant glioma. Cancer Res 55: 2936-2944
20. Yonehara S, Ishii A, Yonehara M (1989) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-down-regulated with the receptor for tumor necrosis factor. J Exp Med 169: 1747-1756